| Name | MT-802 |
|---|---|
| Synonyms |
2-[2-[2-[4-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]ethoxy]ethoxy]-N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]acetamide
Acetamide, 2-[2-[2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]ethoxy]ethoxy]-N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl] MT-802, 10 mM in DMSO 2-[2-[2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]ethoxy]ethoxy]-N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl] 2-(2-(2-(4-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)acetamide MT802,inhibit,Inhibitor,Btk,Bruton tyrosine kinase,MT-802,MT 802,PROT |
| Description | MT-802 is a potent BTK degrader based on PROTAC technology, with a DC50 of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL)[1]. |
|---|---|
| Related Catalog | |
| Target |
DC50: 1 nM (BTK)[1]. |
| In Vitro | MT-802 degrades BTK with a DC50 of 9.1 nM with maximal degradation being observed by 250 nM[1]. |
| References |
| Molecular Formula | C41H41N9O8 |
|---|---|
| Molecular Weight | 787.82 |
| Storage condition | -20°C |